Summary
The development of topical corticosteroids has enabled many dermatoses to be more effectively treated than previously, but there is also no doubt that misuse of these preparations can lead to troublesome local effects and potentially serious systemic problems.
The most effective assay for comparing different compounds has been their vasoconstrictive activity, and this on the whole correlates well with clinical effect. To be effective, the corticosteroid must be absorbed and the importance of concentration, occlusion, the type of vehicle, added penetrants such as urea and the anatomical site, on the amount of absorption and therefore on clinical activity has been demonstrated. Ointments have been shown to be more effective than creams but because of the considerable choice of potencies now available most dermatologists tend to prescribe the different formulations according to the wishes of the patient. For the same reason, dilution of the commercially marketed preparations is now not generally recommended.
The main therapeutic activity of topical corticosteroids is their nonspecific anti-inflammatory effect, thought to be primarily a result of their action on the chemical mediators of inflammation. They have also been shown to be antimitotic which may well be relevant not only to the treatment of scaling dermatoses but also to their dermal thinning effect resulting from inhibition of fibroblasts.
Combinations of corticosteroids with antibacterial and antifungal agents have been shown to be very effective in flexural eruptions and secondarily infected dermatoses.
As a general rule, the use of topical corticosteroids in outpatients, unless badly misused, is not associated with any significant risk of adrenal axis suppression, but care must be exercised as to the amount prescribed, especially if large areas of the body are to be treated with highly potent preparations. Certain groups such as young children and patients with liver failure, and certain anatomical sites such as the flexures and face appear much more prone to side effects, and in these cases mild or moderate compounds should be used in preference to the stronger preparations.
Similar content being viewed by others
References
Ayres, P.J.W, and Hooper, G.: Assessment of the skin penetration properties of different carrier vehicles for topically applied cortisol. British Journal of Dermatology 99: 307–317 (1978).
Baker, H.: Corticosteroids and pustular psoriasis. British Journal of Dermatology 94(Suppl. 12): 83–88 (1976).
Barry, B.W. and Woodford, R.: Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels. British Journal of Dermatology 91: 323–338 (1974).
Barry, B.W. and Woodford, R.: Comparative bio-availability and activity of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty one ointments. British Journal of Dermatology 93: 563–571 (1975).
Barry, B.W. and Woodford, R.: Proprietary hydrocortisone creams. British Journal of Dermatology 95: 423–425 (1976).
Barry, B.W. and Woodford, R.: Vasoconstrictor activities and bioavailabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications. British Journal of Dermatology 97: 555–560 (1977).
Baxter, D.L. and Stoughton, R.B.: Mitotic index of psoriatic lesions treated with anthralin, glucocorticosteroid and occlusion only. Journal of Investigative Dermatology 54: 410–412 (1970).
Bleehen, S.S.: The effect of topical steroids on melanin pigmentation; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.71–76 (Churchill Livingstone, Edinburgh 1976).
Burton, J.L.; Cunliffe, W.J.; Holti, G. and Wright, V.: Complications of topical corticosteroid therapy in patients with liver disease. British Journal of Dermatology 91(Suppl. 10): 22–23 (1974).
Carruthers, J.A.; August, P.J. and Stoughton, R.: Observations on the systemic effects of topical clobetasol propionate. British Medical Journal 4: 203–204 (1975).
Clayton, R.: A double-blind trial of clobetasol propionate (0.05 % ) in the treatment of vitiligo. British Journal of Dermatology 96: 71–73 (1977).
Delforno, C.; Holt, P.J.A. and Marks, R.: Corticosteroid effect on epidermal cell size. British Journal of Dermatology 98: 619–623 (1978).
Du Vivier, A. and Stoughton, R.B.: Acute tolerance to effects of topical glucocorticosteroids. British Journal of Dermatology 94(Suppl. 12): 25–32 (1976).
Dykes, P.J. and Marks, R.: Measurement of skin thickness. A comparison of two in vivo techniques with a conventional histometric method. Journal of Investigative Dermatology 69: 275–278 (1977).
Gell, P.G.H.; Coombs, R.R.A. and Lachmann, P.J.: Clinical Aspects of Immunology (Blackwell Scientific Publications, Oxford 1975).
Greaves, M.W. and Kingston, W.P.: Topical steroids and the pharmacology of inflammation; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.114–120 (Churchill Livingstone, Edinburgh 1976).
Groniowska, M.; Dabrowski, J.; Maciejewski, W. and Walski, M.: Electron-microscopic evaluation of collagen fibrils after topical corticosteroid therapy. Dermatologica 152(Suppl. 1): 147–153 (1976).
Houck, J.C. and Patel, Y.M.: Proposed mode of action of corticosteroids on the connective tissue. Nature (London) 206: 158–160 (1965).
Kaidbey, K.H. and Kligman, A.M.: Assay of topical corticosteroids. Archives of Dermatology 112: 808–810 (1976).
Keczkes, K.; Teasdale, P.; Wiseman, R.A. and Mugglestone, C.J.: Plasma cortisol values after topical application of diflucortolone] valerate (0.3 %) or clobetasol propionate (0.05 %) in psoriatic patients. British Journal of Dermatology 99: 417–420 (1978).
Kirby, J.D. and Munro, D.D.: Steroid-induced atrophy in an animal and human model. British Journal of Dermatology 94(Suppl. 12): 111–123 (1976).
Leyden, J.J. and Kligman, A.M.: The case for steroid-antibiotic combinations. British Journal of Dermatology 96: 179–187 (1977).
McKenzie, A.W. and Stoughton, R.B.: Method for comparing percutaneous absorption of steroids. Archives of Dermatology 86: 608–610 (1962).
Maibach, H.I.: In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 152(Suppl. 1): 11–25 (1976).
Maibach, H.I. and Stoughton, R.B.: Topical corticosteroids; in Azarnoff (Ed) Steroid Therapy pp.174–190 (W.B. Saunders, Philadelphia 1975).
Marks, R. and Williams, K.: The action of topical corticosteroids on the epidermal cell cycle; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.39–46 (Churchill Livingstone, Edinburgh 1976).
Marks, R.; Halprin, K.M.; Fukai, K. and Graff, D.: Topically applied triamcinolone and macromolecular synthesis by human epidermis. Journal of Investigative Dermatology 56: 470–473 (1971).
Marks, R. and Samman, P.D.: Dermatology (Heinemann Medical, London 1977).
Marshall, R.C. and du Vivier, A.: The effects on epidermal DNA synthesis of the butyrate esters of clobetasone and clobetasol and the proprionate ester of clobetasol. British Journal of Dermatology 98: 355–359 (1978).
Munro, D.D.: The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. British Journal of Dermatology 94(Suppl. 12): 67–76 (1976).
Munro, D.D. and Clift, D.C.: Pituitary-adrenal function after prolonged use of topical corticosteroids. British Journal of Dermatology 88: 381–385 (1973).
Munro, D.D. and Wilson, L. (Eds): Steroids and the Skin. British Journal of Dermatology 94: Suppl. 12 (1976).
Pierard, G.E.: Iatrogenic alterations of the biochemical properties of human skin. British Journal of Dermatology 98: 113–114 (1978).
Polano, M.K.; Hagenouw, J.R.B. and Richter, J.R. (Eds): Advances in Topical Corticosteroid Therapy. Dermatologica 152: Suppl. 1 (1976).
Polano, M.K. and Ponec, M.: Dependence of corticosteroid penetration on the vehicle. Archives of Dermatology 112: 675–680 (1976).
Priestley, G.C.: Effects of corticosteroids on the growth and metabolism of fibroblasts cultured from human skin. British Journal of Dermatology 99: 253–261 (1978).
Raab, W.: Effects of local corticosteroids in skin infections. Dermatologica 152(Suppl. 1): 67–79 (1976).
Rasmussen, J.E.: Percutaneous absorption of topically applied triamcinolone in children. Archives of Dermatology 114: 1165–1167 (1978).
Reddy, B.S.N. and Singh, G.: A new model for human bioassay of topical corticosteroids. British Journal of Dermatology 94: 191–193 (1976).
Saarni, H. and Hopsu-havu, V.K.: Inhibition of acid mucopolysac-charide synthesis by hydrocortisone, hydrocortisone-17-buty-rate and betamethasone-17-valerate. British Journal of Dermatology 97: 505–507 (1977).
Sim, A.W.; Picton, W.; Fox, P.K. and Walker, G.B.: The effect of topical corticosteroids on the metabolism of dermal collagen; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.89–96 (Churchill Livingstone, Edinburgh 1976).
Snell, E.S.: Mechanisms of glucocorticoid activity — a review; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.136–145 (Churchill Livingstone, Edinburgh 1976).
Sparkes, C.G.: Measuring adrenal function in out-patients using topical corticosteroids. British Journal of Dermatology 94(Suppl. 12): 77–82 (1976).
Stevanovic, D.V.: Corticosteroid induced atrophy of the epidermis; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.97–105 (Churchill Livingstone, Edinburgh 1976).
Stevanovic, D.V.; Wilson, L. and Sparkes, C.G.: A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate. British Journal of Dermatology 96: 67–70 (1977).
Sulzberger, M.B. and Witten, V.H.: The effect of topically applied compound F in selected dermatoses. Journal of Investigative Dermatology 19: 101–102 (1952).
Wachs, G.N. and Maibach, H.I.: Co-operative double-blind trial of an antibiotic corticoid combination in impetiginized atopic dermatitis. British Journal of Dermatology 95: 323–328 (1976).
Walker, S.R.; Wilson, L.; Fry, L. and James, V.H.T.: The effect on plasma corticosteroid levels of the short term application of clobetasol propionate. British Journal of Dermatology 91: 339–343 (1974).
Webster, R.C.; Noonan, P.K. and Maibach, H.I.: Effects of salicylic acid on the percutaneous absorption of hydrocortisone. Archives of Dermatology 114: 1162–1164 (1978).
Weissmann, G. and Thomas, L.: Studies on lysosomes. 1. The effects of endotoxin, endotoxin tolerance and cortisone on the release of acid hydrolases from a granular fraction of rabbit liver. Journal of Experimental Medicine 116: 433–450 (1962).
Wells, G.C.: The effect of hydrocortisone on standardized skin surface trauma. British Journal of Dermatology 69: 11–18 (1957).
Whitefield, M. and McKenzie, A.W.: A new formulation of 0.1 % hydrocortisone cream with vasoconstrictor activity and clinical effectiveness. British Journal of Dermatology 92: 585–588 (1975).
Wilson, L.C. and Marks, R. (Eds): Mechanisms of Topical Corticosteroid Activity (Churchill Livingstone, Edinburgh 1976).
Wilson Jones, E.: Steroid atrophy — a histological appraisal. Dermatologica 152(Suppl. 1): 107–115 (1976).
Winter, G.D.: Epidermal wound healing in corticosteroid treated skin of the domestic pig; in Wilson and Marks (Eds) Mechanisms of Topical Corticosteroid Activity, pp.61–70 (Churchill Livingstone, Edinburgh 1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, J.A., Munro, D.D. Topical Corticosteroids: Clinical Pharmacology and Therapeutic Use. Drugs 19, 119–134 (1980). https://doi.org/10.2165/00003495-198019020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198019020-00004